Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors

Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors

(2021) Kevin Tyan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors

(2020) Chiaki Kurimoto et al.   CANCER SCIENCE

Impact of the gut microbiome on immune checkpoint inhibitor efficacy— a systematic review

(2020) J. Pierrard et al.   Current Oncology

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

(2020) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Gut microbiota-derived metabolites as key actors in inflammatory bowel disease

(2020) Aonghus Lavelle et al.   Nature Reviews Gastroenterology & Hepatology

Signaling networks in immunometabolism

(2020) Jordy Saravia et al.   CELL RESEARCH

The Gut Microbiota: Emerging Evidence in Autoimmune Diseases

(2020) Xuan Zhang et al.   TRENDS IN MOLECULAR MEDICINE

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

(2020) Adrienne M. Luoma et al.   CELL

Neurological autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes

(2020) Elia Sechi et al.   NEUROLOGY

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

(2020) Sheng Liu et al.   Protein & Cell

Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases

(2020) Yun Liu et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Immune checkpoint inhibitor-associated celiac disease

(2020) Yousef Badran et al.   Journal for ImmunoTherapy of Cancer

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients

(2020) Francesco Sabbatino et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

(2020) Erez N. Baruch et al.   SCIENCE

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis

(2020) Zsofia D. Drobni et al.   Journal of the American Heart Association

Fine-Tuning Cytokine Signals

(2019) Jian-Xin Lin et al.   Annual Review of Immunology

Dysregulated Lung Commensal Bacteria Drive Interleukin-17B Production to Promote Pulmonary Fibrosis through Their Outer Membrane Vesicles

(2019) Daping Yang et al.   IMMUNITY

Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).

(2019) Rika Kizawa et al.   JOURNAL OF CLINICAL ONCOLOGY

The pathogenicity of Th17 cells in autoimmune diseases

(2019) Keiko Yasuda et al.   Seminars in Immunopathology

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

(2019) Gregory S. Phillips et al.   JOURNAL OF CLINICAL ONCOLOGY

Myasthenia Gravis Induced by Immune Checkpoint Inhibitors

(2019) Ondine Becquart et al.   JOURNAL OF IMMUNOTHERAPY

Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy

(2019) Anastasia Zekeridou et al.   MAYO CLINIC PROCEEDINGS

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: A mini review

(2019) Xiaowen Sun et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions

(2019) Francesca Romana Mariotti et al.   Frontiers in Immunology

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

(2019) Alexander Faje et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis

(2019) Karthik Suresh et al.   JOURNAL OF CLINICAL INVESTIGATION

Immuno-oncology drug development goes global

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

A case of checkpoint inhibitor-induced celiac disease

(2019) Dana Alsaadi et al.   Journal for ImmunoTherapy of Cancer

Cytokines in Inflammatory Disease

(2019) Shinwan Kany et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

(2019) Khashayar Esfahani et al.   Nature Communications

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

(2018) Karen Kelly et al.   CANCER

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

(2018) Adriana T. Lopez et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

(2018) Joy Hsu et al.   JOURNAL OF CLINICAL INVESTIGATION

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

(2018) Su Y. Lim et al.   CLINICAL CANCER RESEARCH

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

(2018) Omar Hasan Ali et al.   EUROPEAN JOURNAL OF CANCER

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

(2018) Emma C. de Moel et al.   Cancer Immunology Research

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis

(2018) Ke Ma et al.   Frontiers in Pharmacology

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Is autoimmunity the Achilles' heel of cancer immunotherapy?

(2017) Carl H June et al.   NATURE MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

(2017) Guillermo De Velasco et al.   Cancer Immunology Research

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors

(2017) Heinz Läubli et al.   OncoImmunology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

(2016) David Y. Oh et al.   CANCER RESEARCH

Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis

(2016) O. Abdel-Rahman et al.   CLINICAL ONCOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

(2016) Sumit K. Subudhi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

(2015) Andras Perl   Annals of the New York Academy of Sciences

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

The expanding family of regulatory B cells

(2015) Claudia Mauri et al.   INTERNATIONAL IMMUNOLOGY

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

PD-L1hi B cells are critical regulators of humoral immunity

(2015) Adnan R. Khan et al.   Nature Communications

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

mTOR signaling, Tregs and immune modulation

(2014) Nicole M Chapman et al.   Immunotherapy

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

(2014) H. S. Kuehn et al.   SCIENCE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity

(2009) Eli M Eisenstein et al.   PEDIATRIC RESEARCH